Purpose
Patients who have experienced anaphylaxis are observed in a setting with facilities to manage deterioration or a biphasic reaction.
Purpose
To avoid harm resulting from delayed administration of adrenaline to patients with anaphylaxis who have their own adrenaline injector and could self-medicate safely during a healthcare encounter or admission.
Purpose
To reduce adverse outcomes during or after anaphylaxis due to low blood pressure. Fatality can occur within minutes if a patient stands or sits up suddenly while they have inadequate perfusion.
Purpose
To ensure immediate treatment with intramuscular adrenaline as soon as anaphylaxis is recognised or suspected and prevent progression to life-threatening symptoms.
Purpose
To improve the time to optimal diagnosis and treatment for people with anaphylaxis.
Quality statements
The Acute Anaphylaxis Clinical Care Standard includes six quality statements. By describing what each statement means, the standard supports:
The quality statements in the Acute Anaphylaxis Clinical Care Standard describe the expected standard for key components of patient care.
What do clinicians need to know?
The Commission, in collaboration with the Therapeutic Goods Administration (TGA) and the Australian Government Department of Health is undertaking a project to develop and pilot the Australian Unique Device Identifier Framework (UDI Framework) for Australian health service organisations (UDI4H).